Sinovac Biotech Ltd (NASDAQ:SVA)
| 3.40 Data as of May 21 |  0.00 / 0.00%Today’s Change | 1.72 Today|||52-Week Range 5.09 | +8.28% Year-to-Date |
Latest SVA News | Press Releases
No recent news for Sinovac Biotech Ltd.
Today’s Trading
| Previous close | 3.40 |
| Today’s open | n.a. |
| Day’s range | -- - -- |
| Volume | 0 |
| Average volume (3 months) | 492,507 |
| Market cap | $187.3M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/21/2013
Growth & Valuation
| Earnings growth (last year) | +87.50% |
| Earnings growth (this year) | -1,300.00% |
| Earnings growth (next 5 years) | +12.00% |
| Revenue growth (last year) | +70.18% |
| P/E ratio | NM |
| Price/Sales | 2.11 |
| Price/Book | 1.43 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CORTCorcept Therapeutics... | 0.00 | 0.00% |
| PRTAProthena Corporation... | 0.00 | 0.00% |
| DRTXDurata Therapeutics ... | 0.00 | 0.00% |
| SUPNSupernus Pharmaceuti... | 0.00 | 0.00% |
Data as of 4:00pm ET, 05/21/2013
Financials
| Next reporting date | May 28, 2013 |
| EPS forecast (this quarter) | -$0.10 |
| Annual revenue (last year) | $56.8M |
| Annual profit (last year) | -$844.7K |
| Net profit margin | -1.49% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chairman, President, CEO & Secretary Wei Dong Yin, MD, MBA |
Chief Financial Officer Danny Chung, CPA |
Corporate headquarters Beijing, Beijing |
Forecasts
